Dr. Paul A. Bunn
Head, Division of Medical Oncology
13001 E. 17th Place
Aurora, CO 80045
Weill Cornell Medical College - 1971
University of California San Francisco
National Capital Consortium (Bethesda) Program
Dr. Paul A. Bunn, Jr. leads the Division of Medical Oncology at the University of Colorado Denver School of Medicine, where he has practiced and taught since 1984. Dr. Bunn served as director of the University of Colorado Cancer Center from 1986 to 2009 and is the university’s James Dudley Chair in Cancer Research. Dr. Bunn also serves as executive director of the International Association for the Study of Lung Cancer.
Dr. Bunn received his B.A. from Amherst College in Amherst, Massachusetts, and received his M.D. from Weill Cornell Medical College in New York City. He completed an internship and residency at the University of California San Francisco and a fellowship in medical oncology at the National Capital Consortium (Bethesda) Program. He is board certified in internal medicine and medical oncology.
Clinical and Laboratory Research
The author of hundreds of articles, reviews and book chapters, Dr. Bunn’s research is well known in the cancer world. He focuses primarily on novel therapies for lung cancer. Dr. Bunn has led numerous national and local trials regarding the treatment of lung cancer, and his findings are credited with setting standards in the treatment of the disease.
Dr. Bunn has researched alternative chemotherapy drugs for lung cancer that would hopefully cause fewer side effects than traditional, intravenous chemotherapy. He has also studied the genetics of the disease, seeking to learn how gene therapy could be used to combat the disease. He is currently taking part in research funded by the National Institutes of Health and the National Cancer Institute that aims to establish a Specialized Program in Research Excellence in Lung Cancer to expand understanding about the biology of the disease, as well as to find new methods of diagnosis, prevention and treatment.
Dr. Bunn has been president of the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer (where he currently serves as executive director), and the Association of American Cancer Institutes. He has also served as an expert on topics of drug regulation for government officials as chairman of the U.S. Food and Drug Administration’s Oncology Drug Advisory Committee.
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.
Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, Dziadziuszko R, Richardson K, Richardson F, Wacker B, Sternberg DW, Rusk J, Franklin WA, Varella-Garcia M, Bunn PA Jr, Camidge DR. J Clin Oncol. 2011 Sep 10; 29(26):3567-73. Epub 2011 Aug 8.
Genetic testing for lung cancer: reflex versus clinical selection.
Bunn PA Jr, Doebele RC. J Clin Oncol. 2011 May 20; 29(15):1943-5. Epub 2011 Apr 11. No abstract available.
Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent.
Solomon B, Bunn PA Jr. Future Oncol. 2005 Dec; 1(6):733-46. Review.
Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma.
Sugita M, Geraci M, Gao B, Powell RL, Hirsch FR, Johnson G, Lapadat R, Gabrielson E, Bremnes R, Bunn PA, Franklin WA. Cancer Res. 2002 Jul 15; 62(14):3971-9.
Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors).
Bunn PA Jr. Semin Oncol. 2002 Jun; 29(3 Suppl 9): 17-22. Review.
Future directions in the development of pemetrexed.
Calvert H, Bunn PA Jr. Semin Oncol. 2002 Apr;29(2 Suppl 5):54-61. Review.
Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux.
Cohen AJ, Bunn PA, Franklin W, Magill-Solc C, Hartmann C, Helfrich B, Gilman L, Folkvord J, Helm K, Miller YE. Cancer Res. 1996 Feb 15; 56(4):831-9.
University of Colorado School of Medicine – Paul A. Bunn, Jr., M.D.